Future research should evaluate the immunomodulatory benefits of LRH‐1/NR5A2 agonists in newly diagnosed individuals and different age groups to optimise its clinical application and improve outcomes in T1D therapy. This evidence concerns the gene NR5A2 and type 1 diabetes mellitus.